ADVA Biotechnologies
Ms. Hadar has over 20 years of experience in senior financial positions leading teams and organizations' growth, managing M&A processes, financing rounds, and reorganization activities. Ms. Hadar has a strong background in accounting, FP&A, and international tax planning. Prior to joining Adva, Ms. Hadar was the group CFO of Gevasol, a privately held global industrial group, prior to that served as the CFO of two medical device start-ups that went through major acquisitions. Ms. Hadar is a certified public accountant and received her B.A. in economics and accounting from Haifa University, a Master's degree in Law studies from Bar Ilan University, and an EMBA from Kellogg School of Management at Northwestern University.
ADVA Biotechnologies
ADVA Biotechnology develops enabling technologies for cell therapy manufacturing. The company has developed ADVA X3, a robust, modular cell-manufacturing cGMP system based on a single-use end-to-end solution.ADVA X3 enables autologous cell therapy manufacturing at the bedside, allowing optimization, tight quality assurance, improved availability,reduced time to market, and significant cost reduction. The automated platform is designed to enable autologous manufacturing of additional types of cells with a change in the disposable chamber, allowing efficiency and flexibility with a long pipeline of products.